Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.

Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H
Am J Kidney Dis. 2010 55 (1): 50-60

PMID: 19932542 · PMCID: PMC2804955 · DOI:10.1053/j.ajkd.2009.08.019

MeSH Terms (18)

Adalimumab Adolescent Adult Anti-Inflammatory Agents Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Child Child, Preschool Dose-Response Relationship, Drug Female Follow-Up Studies Glomerular Filtration Rate Glomerulosclerosis, Focal Segmental Humans Male Treatment Outcome Tumor Necrosis Factor-alpha Young Adult

Connections (2)

This publication is referenced by other Labnodes entities: